Spring til hovednavigation
Spring til søgning
Spring til hovedindhold
Region Hovedstadens forskningsportal Forside
Hjælp og OSS
Dansk
English
Forside
Hospitaler/afdelinger
Forskere
Publikationer
Aktiviteter
Priser
Søg efter ekspertise, navn eller tilknytning
Should immunologic strategies be incorporated into frontline ALL therapy?
Cecilie Utke Rank
, Wendy Stock
Afdeling for Blodsygdomme
2
Citationer (Scopus)
Oversigt
Fingeraftryk
Fingeraftryk
Dyk ned i forskningsemnerne om 'Should immunologic strategies be incorporated into frontline ALL therapy?'. Sammen danner de et unikt fingeraftryk.
Sorter
Vægt
Alfabetisk
Keyphrases
Acute Lymphoblastic Leukemia
100%
Leukemia Therapy
100%
Adult Patients
33%
Treatment Strategy
33%
Older Adults
33%
Chemotherapy
33%
Treatment Options
16%
All Ages
16%
Overall Survival
16%
Survival Rate
16%
Older Patients
16%
Adaptation
16%
Rituximab
16%
CD20
16%
CD19
16%
Treatment Protocol
16%
Chemotherapy Toxicity
16%
T-cell Acute Lymphoblastic Leukemia (T-ALL)
16%
CD38
16%
Antibody Targeting
16%
Gemtuzumab Ozogamicin
16%
Minimal Residual Disease
16%
Immunotherapeutics
16%
Treatment Toxicity
16%
Targeted Treatment
16%
Attendants
16%
Event-free Survival
16%
Leukemia Subtype
16%
Multiagent Chemotherapy
16%
Chimeric Antigen Receptor T Cells (CAR-T)
16%
One-size-fits-all
16%
B-cell Acute Lymphoblastic Leukemia (B-ALL)
16%
Frontline Treatment
16%
Agent Behavior
16%
Pediatric Inspired
16%
CD22
16%
Blinatumomab
16%
Medicine and Dentistry
Acute Lymphoblastic Leukemia
100%
Survival Rate
14%
Overall Survival
14%
Targeted Therapy
14%
Pediatrics
14%
Rituximab
14%
CD20
14%
Minimal Residual Disease
14%
Immunotherapy
14%
Event Free Survival
14%
Chimeric Antigen Receptor T-Cell Immunotherapy
14%
Acute B-Cell Lymphoblastic Leukemia
14%
Chemotherapy Agent
14%
Blinatumomab
14%
Inotuzumab Ozogamicin
14%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Lymphoblastic Leukemia
100%
Chemotherapy
37%
Immunotherapy
25%
Overall Survival
12%
Rituximab
12%
Minimal Residual Disease
12%
Survival Rate
12%
Event Free Survival
12%
Chimeric Antigen Receptor
12%
Chemotherapy Agent
12%
Blinatumomab
12%
Inotuzumab Ozogamicin
12%
Nursing and Health Professions
Acute Lymphoblastic Leukemia
100%
Survival Rate
12%
Rituximab
12%
Overall Survival
12%
Minimal Residual Disease
12%
Event Free Survival
12%
Immunotherapy
12%
Inotuzumab Ozogamicin
12%
Chimeric Antigen Receptor T-Cell Immunotherapy
12%
Blinatumomab
12%